Literature DB >> 24637687

Efficacy and tolerability of micafungin monotherapy for candidemia and deep-seated candidiasis in adults with cancer.

Dimitrios Farmakiotis1, Jeffrey J Tarrand2, Dimitrios P Kontoyiannis1.   

Abstract

The response rate among 58 patients with cancer and candidemia or deep-seated candidiasis treated with micafungin monotherapy was 81%. Intensive care unit (ICU) stay, concomitant nonfungal infections, and acute kidney injury were significantly associated with the 30-day crude mortality rate. Severe neutropenia was an independent predictor of micafungin failure. The efficacy and safety of micafungin in cancer patients with invasive candidiasis were comparable to those reported for patients without malignancy and for cancer patients treated with caspofungin.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24637687      PMCID： PMC4068486          DOI： 10.1128/AAC.00051-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

Review 1.  Antifungal therapy with an emphasis on biofilms.

Authors:  Christopher G Pierce; Anand Srinivasan; Priya Uppuluri; Anand K Ramasubramanian; José L López-Ribot
Journal:  Curr Opin Pharmacol       Date:  2013-09-04       Impact factor: 5.547

2.  Efficacy and safety of micafungin for treatment of serious Candida infections in patients with or without malignant disease.

Authors:  Oliver A Cornely; Francisco M Marty; Flavie Stucker; Peter G Pappas; Andrew J Ullmann
Journal:  Mycoses       Date:  2011-06-13       Impact factor: 4.377

3.  Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death.

Authors:  Monica A Slavin; Tania C Sorrell; Deborah Marriott; Karin A Thursky; Quoc Nguyen; David H Ellis; C Orla Morrissey; Sharon C-A Chen
Journal:  J Antimicrob Chemother       Date:  2010-03-04       Impact factor: 5.790

4.  Efficacy and safety of micafungin as an empirical therapy for invasive fungal infections in patients with hematologic disorders: a multicenter, prospective study.

Authors:  Masaki Yamaguchi; Toshiro Kurokawa; Ken Ishiyama; Go Aoki; Mikio Ueda; Sadaya Matano; Akiyoshi Takami; Hirohito Yamazaki; Aiko Sawazaki; Hiromasa Yamauchi; Takashi Yoshida; Shinji Nakao
Journal:  Ann Hematol       Date:  2011-06-22       Impact factor: 3.673

5.  Caspofungin for invasive candidiasis at a tertiary care medical center.

Authors:  Aimee K Zaas; Elizabeth S Dodds Ashley; Barbara D Alexander; Melissa D Johnson; John R Perfect
Journal:  Am J Med       Date:  2006-11       Impact factor: 4.965

6.  Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial.

Authors:  Ernst-Rüdiger Kuse; Ploenchan Chetchotisakd; Clovis Arns da Cunha; Markus Ruhnke; Carlos Barrios; Digumarti Raghunadharao; Jagdev Singh Sekhon; Antonio Freire; Venkatasubramanian Ramasubramanian; Ignace Demeyer; Marcio Nucci; Amorn Leelarasamee; Frédérique Jacobs; Johan Decruyenaere; Didier Pittet; Andrew J Ullmann; Luis Ostrosky-Zeichner; Olivier Lortholary; Sonja Koblinger; Heike Diekmann-Berndt; Oliver A Cornely
Journal:  Lancet       Date:  2007-05-05       Impact factor: 79.321

7.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Authors:  Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

8.  Anidulafungin versus caspofungin in a mouse model of candidiasis caused by anidulafungin-susceptible Candida parapsilosis isolates with different degrees of caspofungin susceptibility.

Authors:  Dimitra Dimopoulou; Georgios Hamilos; Maria Tzardi; Russell E Lewis; George Samonis; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2013-10-21       Impact factor: 5.191

9.  Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy.

Authors:  Anastasia Antoniadou; Harrys A Torres; Russell E Lewis; John Thornby; Gerald P Bodey; Jeffrey P Tarrand; Xiang-Yang Han; Kenneth V I Rolston; Amar Safdar; Issam I Raad; Dimitrios P Kontoyiannis
Journal:  Medicine (Baltimore)       Date:  2003-09       Impact factor: 1.889

10.  Monotherapy with caspofungin for candidaemia in adult patients with cancer: a retrospective, single institution study.

Authors:  Nikolaos V Sipsas; Russell E Lewis; Issam I Raad; Dimitrios P Kontoyiannis
Journal:  Int J Antimicrob Agents       Date:  2009-02-28       Impact factor: 5.283
View more
  2 in total

1.  Pharmacodynamics of a Long-Acting Echinocandin, CD101, in a Neutropenic Invasive-Candidiasis Murine Model Using an Extended-Interval Dosing Design.

Authors:  Alexander J Lepak; Miao Zhao; Brian VanScoy; Paul G Ambrose; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

2.  Micafungin versus anidulafungin in critically ill patients with invasive candidiasis: a retrospective study.

Authors:  Patrick J van der Geest; Nicole G M Hunfeld; Sophie E Ladage; A B Johan Groeneveld
Journal:  BMC Infect Dis       Date:  2016-09-15       Impact factor: 3.090
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.